Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Microbio (Shanghai) Co. Ltd. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter involves 1 distinct examiner and 1 distinct art unit, so the available data identifies one direct prosecution path.
KONOPKA, CATHERINE ANNE is the busiest examiner, with 1 pending matter. The response can be managed through a focused review of the pending claims, the cited issues, and the art unit’s biotechnology examination context.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KONOPKA, CATHERINE ANNE | 1 | 57.0% | +66.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18715175 | MODIFICATION PATTERNS FOR SMALL INTERFERING RNA MOLECULES WITH HIGH STABILITY AND GENE SILENCING ACTIVITIES | KONOPKA, CATHERINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18715175 | MODIFICATION PATTERNS FOR SMALL INTERFERING RNA MOLECULES WITH HIGH STABILITY AND GENE SILENCING ACTIVITIES | KONOPKA, CATHERINE ANNE | 1635 | §102§103DP | Non-Final OA | — | Pending | May 31, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMicrobio (Shanghai) Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Catherine Anne Konopka has the most, with 1 of Microbio (Shanghai) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.